These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 29401498)
1. Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures. Afify EAMR; Elsayed I; Gad MK; Mohamed MI; Afify AEMR PLoS One; 2018; 13(2):e0191415. PubMed ID: 29401498 [TBL] [Abstract][Full Text] [Related]
2. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516 [TBL] [Abstract][Full Text] [Related]
3. Cubogel as potential platform for glaucoma management. Sayed S; Abdel-Moteleb M; Amin MM; Khowessah OM Drug Deliv; 2021 Dec; 28(1):293-305. PubMed ID: 33509004 [TBL] [Abstract][Full Text] [Related]
4. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation. Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SOA; Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG Int J Pharm; 2019 Oct; 570():118662. PubMed ID: 31491481 [TBL] [Abstract][Full Text] [Related]
5. Topical drug delivery to the eye: dorzolamide. Loftsson T; Jansook P; Stefánsson E Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010 [TBL] [Abstract][Full Text] [Related]
6. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468 [TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. Liu R; Liu Z; Zhang C; Zhang B J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401 [TBL] [Abstract][Full Text] [Related]
8. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Kouchak M; Malekahmadi M; Bavarsad N; Saki Malehi A; Andishmand L Drug Dev Ind Pharm; 2018 Aug; 44(8):1239-1242. PubMed ID: 28956449 [TBL] [Abstract][Full Text] [Related]
9. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits. Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071 [TBL] [Abstract][Full Text] [Related]
10. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA; Wilde MI Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858 [TBL] [Abstract][Full Text] [Related]
11. Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation. Kouchak M; Mahmoodzadeh M; Farrahi F AAPS PharmSciTech; 2019 Jun; 20(5):210. PubMed ID: 31161269 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of dorzolamide. Martens-Lobenhoffer J; Banditt P Clin Pharmacokinet; 2002; 41(3):197-205. PubMed ID: 11929320 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent]. Kobayashi M; Naito K Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564 [TBL] [Abstract][Full Text] [Related]
14. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dubey V; Mohan P; Dangi JS; Kesavan K Int J Biol Macromol; 2020 Jun; 152():1224-1232. PubMed ID: 31751741 [TBL] [Abstract][Full Text] [Related]
15. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. Ammar HO; Salama HA; Ghorab M; Mahmoud AA AAPS PharmSciTech; 2009; 10(3):808-19. PubMed ID: 19536653 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure. Huang Q; Rui EY; Cobbs M; Dinh DM; Gukasyan HJ; Lafontaine JA; Mehta S; Patterson BD; Rewolinski DA; Richardson PF; Edwards MP J Med Chem; 2015 Mar; 58(6):2821-33. PubMed ID: 25728019 [TBL] [Abstract][Full Text] [Related]
17. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Maus TL; Larsson LI; McLaren JW; Brubaker RF Arch Ophthalmol; 1997 Jan; 115(1):45-9. PubMed ID: 9006424 [TBL] [Abstract][Full Text] [Related]
18. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Kadam RS; Jadhav G; Ogidigben M; Kompella UB Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129 [TBL] [Abstract][Full Text] [Related]
19. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Ingram CJ; Brubaker RF Am J Ophthalmol; 1999 Sep; 128(3):292-6. PubMed ID: 10511022 [TBL] [Abstract][Full Text] [Related]
20. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N; Nakrani H; Raval M; Sheth N Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]